TITLE

Excellent Response Rate to a Double Dose of the Combined Hepatitis A and B Vaccine in Previous Nonresponders to Hepatitis B Vaccine

AUTHOR(S)
Cardell, Kristina; Åkerlind, Britt; Sällberg, Matti; Frydén, Aril
PUB. DATE
August 2008
SOURCE
Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p299
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background. Hepatitis B vaccine has been shown to be highly efficient in preventing hepatitis B. However, 5%-10% of individuals fail to develop protective levels (⩾10 mIU/mL) of antibodies to hepatitis B surface antigen (anti-HBs) and are considered to be nonresponders. Methods. A total of 48 nonresponders and 20 subjects naive to the HBV vaccine received a double dose of combined hepatitis A and B vaccine (Twinrix) at 0, 1, and 6 months. The levels of anti-HBs and antibodies to hepatitis A virus (anti-HAV) were determined before vaccination and 1 month after each dose. Results. Among 44 nonresponders, protective anti-HBs levels were found in 26 (59%) after the first dose and in 42 (95%) after the third dose. Among the control subjects, the corresponding figures were 10% and 100%, respectively. All subjects seroconverted to anti-HAV. The titers of both anti-HBs and anti-HAV were lower in the previously nonresponsive subjects (P < .01). Conclusion. Revaccination of nonresponders to the standard hepatitis B vaccine regimen with a double dose of the combined hepatitis A and B vaccine was highly effective. This is most likely explained by the increased dose, a positive bystander effect conferred by the hepatitis A vaccine, or both.
ACCESSION #
33359015

 

Related Articles

  • Can Specific Heterologous Immunity Boost Hepatitis B Vaccine Responses? Diepolder, Helmut M. // Journal of Infectious Diseases;8/1/2008, Vol. 198 Issue 3, p297 

    The article discusses the effect of a specific heterologous immunity in boosting Hepatitis B Vaccinne responses. The currently licensed hepatitis B vaccines are highly effective and induce protective antibody titers in 95% of vaccines after three immunizations. Moreover, immunogenicity of the...

  • Hepatitis B vaccine: the horizon and beyond. Coleman, J. C. // Journal of the Royal Society of Medicine;Apr1984, Vol. 77 Issue 4, p335 

    The article discusses developments in the treatment of hepatitis B virus (HBV). It is asserted that the development of the first-generation vaccines against HBV may afford a unique opportunity to intervene in the natural history of a human tumor by immunoprophylaxis. The circumstances that led...

  • Vaccines to prevent chronic hepatitis C virus infection: current experimental and preclinical developments. Wintermeyer, Philip; Wands, Jack R. // Journal of Gastroenterology;Jun2007, Vol. 42 Issue 6, p424 

    The article presents a study regarding the development of various vaccines for chronic hepatitis C virus (HCV) infection. This study is not intended to be a discussion of HCV vaccination approaches, but rather will focus on emerging models that may contribute to a better understanding of how to...

  • National Survey of Hepatitis Testing and Vaccination Services Provided by Drug Services in England and Wales. Winstock, A. J.; Sheridan, J.; Lovell, S.; Farrell, M.; Strang, J. // European Journal of Clinical Microbiology & Infectious Diseases;Nov2000, Vol. 19 Issue 11, p823 

    Since viral hepatitis among intravenous drug users continues to be a major cause of morbidity and mortality, the present study was conducted to survey drug agencies in England and Wales in order to identify the prevalence of hepatitis B and C testing and vaccination being provided. A postal...

  • Toolbox for Non-Intrusive Structural and Functional Analysis of Recombinant VLP Based Vaccines: A Case Study with Hepatitis B Vaccine. Mulder, Anke M.; Carragher, Bridget; Towne, Victoria; Yuan Meng; Yang Wang; Dieter, Lance; Potter, Clinton S.; Washabaugh, Michael W.; Sitrin, Robert D.; Qinjian Zhao // PLoS ONE;Apr2012, Vol. 7 Issue 4, p1 

    Background: Fundamental to vaccine development, manufacturing consistency, and product stability is an understanding of the vaccine structure-activity relationship. With the virus-like particle (VLP) approach for recombinant vaccines gaining popularity, there is growing demand for tools that...

  • Liver cirrhosis: Child–Pugh grading of cases seen in Nigeria. Ndububa, D. A.; Ojo, O. S.; Aladegbaiye, A. O.; Adebayo, R. A.; Adetiloye, V. A.; Durosinmi, M. A. // Tropical Doctor;Jul2005, Vol. 35 Issue 3, p169 

    Child–Pugh grading is an important determinant of treatment options, surgical interventions and prognosis in chronic liver disease. Sixty-four liver cirrhosis patients (49 men, 15 women) seen at Ile-Ife, Nigeria were graded according to the Child–Pugh parameters. Only one (1.6%)...

  • HBvaxPRO.  // Royal Society of Medicine: Medicines;2002, p279 

    The article presents information on HBvaxPRO, a proprietary, prescription-only preparation of hepatitis B vaccine. It can be used to protect people at risk from infection with hepatitis B, and is available in a form for injection.

  • Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 22-Year Follow-Up Study and Response to a Booster Dose. McMahon, Brian J.; Dentinger, Catherine M.; Bruden, Dana; Zanis, Carolyn; Peters, Helen; Hurlburt, Debbie; Bulkow, Lisa; Fiore, Anthony E.; Bell, Beth P.; Hennessy, Thomas W. // Journal of Infectious Diseases;11/1/2009, Vol. 200 Issue 9, p1390 

    Background. The duration of protection in children and adults (including health care workers) resulting from the hepatitis B vaccine primary series is unknown. Methods. To determine the protection afforded by hepatitis B vaccine, Alaska Native persons who had received plasma-derived hepatitis B...

  • Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. Whittle, Hilton; Jaffar, Shabbar; Wansbrough, Michael; Mendy, Maimuna; Dumpis,, Uga; Collinson, Andrew; Hall, Andrew // BMJ: British Medical Journal (International Edition);9/14/2002, Vol. 325 Issue 7364, p569 

    Abstract Objective: To determine the duration of protection from hepatitis B vaccine given in infancy and early childhood. Design: Cross sectional serological study of hepatitis B virus infection in children of various ages 14 years after the start of a trial of vaccination regimens. Setting:...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics